Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Assembly Biosciences, Inc. (NASDAQ: ASMB).

Full DD Report for ASMB

You must become a subscriber to view this report.


Recent News from (NASDAQ: ASMB)

Assembly Biosciences to Present at Upcoming Investor Conferences
SAN FRANCISCO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in September: Baird Global Healthcare Conference: Uri Lopatin, MD, Chief Medical Officer, wil...
Source: GlobeNewswire
Date: August, 28 2018 07:05
Analysis: Positioning to Benefit within Amtech, NL Industries, Dova Pharmaceuticals, Sientra, Dorian LPG, and Assembly Biosciences - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amtech Systems, Inc. (NASDAQ:ASYS), NL Industries, Inc. (NYSE:NL), Dova P...
Source: GlobeNewswire
Date: August, 16 2018 07:35
Assembly Biosciences misses by $0.44, misses on revenue
Assembly Biosciences (NASDAQ: ASMB ): Q2 EPS of -$1.30 misses by $0.44 . More news on: Assembly Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 08 2018 17:09
Assembly Biosciences Announces Second Quarter 2018 Financial Results
-  ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019 -  Strong Balance Sheet Provides Significant Runway SAN FRANCISCO and INDIANAPOLIS, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:...
Source: GlobeNewswire
Date: August, 08 2018 16:05
Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B Virus Infection
INDIANAPOLIS and SAN FRANCISCO, July 25, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H0731 for the treatment of patients with chronic Hepatitis B i...
Source: GlobeNewswire
Date: July, 25 2018 07:05
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
INDIANAPOLIS and SAN FRANCISCO, July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock to the public at $36.00 per sha...
Source: GlobeNewswire
Date: July, 16 2018 16:05
Assembly Biosciences announces pricing of common stock
Assembly Biosciences (NASDAQ: ASMB ) priced public offering of 4M common at $36/share for gross proceeds of $144M. More news on: Assembly Biosciences, Inc., , Read more ...
Source: SeekingAlpha
Date: July, 11 2018 22:43
Assembly Biosciences Announces Pricing of $144 Million Offering of Common Stock
INDIANAPOLIS and SAN FRANCISCO, July 11, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock to the public at $36.00 per share. The offering is ex...
Source: GlobeNewswire
Date: July, 11 2018 19:28
Assembly Biosciences Initiates Two Phase 2a Trials of ABI-H0731 for the Treatment of Hepatitis B Virus Infection
Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq:ASMB), today announced the initi...
Source: GlobeNewswire
Date: July, 09 2018 07:05
Assembly Biosciences (ASMB) R&D Day Hepatitis B Program - Slideshow
The following slide deck was published by Assembly Biosciences, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 21 2018 15:04

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0838.2337.5038.4137.11120,743
2018-05-1741.9642.5343.1441.28145,036
2017-06-2021.9821.9322.3521.7960,408
2017-06-1921.9221.8822.447721.6279,348
2017-06-1621.7121.7623.0120.9791,814

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-128,57636,38923.5676Cover
2018-12-119,40021,53143.6580Short
2018-12-103,95211,99732.9416Cover
2018-12-078,64617,31749.9278Short
2018-12-0612,08877,99015.4994Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ASMB.


About Assembly Biosciences, Inc. (NASDAQ: ASMB)

Logo for Assembly Biosciences, Inc. (NASDAQ: ASMB)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $865,264,405 - 05/14/2018
    • Authorized: 50,000,000 - 05/01/2018
    • Issue and Outstanding: 20,547,718 - 05/01/2018

     


    Recent Filings from (NASDAQ: ASMB)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 07 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 07 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 19 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 19 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 12 2018
    Preliminary proxy statement providing notification matters to be brought to a vote
    Filing Type: PRE 14AFiling Source: edgar
    Filing Date: April, 06 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 02 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 12 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 08 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: February, 14 2018

     

     


    Daily Technical Chart for (NASDAQ: ASMB)

    Daily Technical Chart for (NASDAQ: ASMB)


    Stay tuned for daily updates and more on (NASDAQ: ASMB)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ASMB)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ASMB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ASMB and does not buy, sell, or trade any shares of ASMB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/